Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
[Interview] Lonza looks beyond manufacturing capacity as biologics grow more complex
3+ hour, 32+ min ago (1035+ words) Zara Asgharpour, head of external innovation at Lonza Biologics, said the contract development and manufacturing organization (CDMO) is looking for technologies that can strengthen its development services and reduce technical risks faced by customers before their products reach manufacturing. “External…...
[Contribution] From ownership to connection: What BIO USA says about the next 50 years of biotech
4+ week, 11+ hour ago (772+ words) Looking back at last year’s BIO USA in Boston, I remember thinking that the event was no longer simply a venue for business development. It had become a place that showed the entire pharmaceutical and biotech value chain, from basic…...
Heuron eyes IPO with Parkinson's, stroke portfolio across four markets
1+ mon, 1+ week ago (546+ words) Korean medical AI company Heuron said it will file a technology assessment application for a Kosdaq stock market listing on Thursday, as it expands its commercial presence in Southeast Asia and Japan. Heuron, which develops AI diagnostic software for brain…...
Former Samsung engineers raise $68 mil. for force-control humanoid technology
1+ mon, 2+ week ago (1494+ words) The question Kim Yong-jae asks about robots is not whether they can walk. The question is whether a robot knows how hard it is gripping. With existing industrial arms, Kim says, a robot assigned to pick up and set down…...
FutureChem to raise ₩40 billion through rights offering to speed up global expansion
1+ mon, 3+ week ago (235+ words) FutureChem is advancing a major growth initiative to accelerate the global commercialization of its radiopharmaceutical therapy (RPT) pipeline. The capital increase is intended to expedite the global commercialization of FC705, the company’s lead prostate cancer therapeutic candidate, while securing financial resources…...
[Interview] Korea’s 1st Alzheimer’s antibody faces cost, access barriers
3+ mon, 6+ hour ago (900+ words) Leqembi (lecanemab), from Eisai and Biogen, reached the Korean market last year for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The drug is meant to be used early, before decline becomes more advanced. In practice,…...
Jenecell inks stem cell deal with Healios to enter K-beauty market
3+ mon, 2+ week ago (286+ words) Jenecell, the Korean offshoot of the Japanese healthcare company Alfresa Corporation, said it signed a 1.4 billion won ($945,000) contract with Healios, a Japanese regenerative medicine developer, to receive bone marrow-derived stem cell conditioned media. Through the agreement, Jenecell has secured a…...
'Most physician-founded startups show weak financial health despite $4.8 million average revenue"
4+ mon, 1+ week ago (437+ words) In Korea, most physician-founded startups have emerged in the past decade, averaging 28 employees and annual revenue of about 7.2 billion won ($4.8 million) as of 2024. However, over half of these startups held a credit rating of C or lower, indicating poor financial…...
[Reporter’s Notebook] Korea’s IPO overcorrection could choke its biotech future
5+ mon, 2+ week ago (634+ words) The ghost of the "Fadu incident" from 2023 -- when the newly listed fabless chipmaker stunned investors with a sharp post-IPO earnings miss -- continues to haunt the Korean stock market in 2026. What began as market shock has hardened into regulatory rigor mortis,…...